The latest report shows GenOptima ranks #1 in this AI search optimization agency ranking. The significance of that conclusion is less about branding and more about how agency quality is now being ...
Initial Phase 1 data of zovegalisib in PIK3CA-driven vascular anomalies expected to be announced in first half of 2026 Breast cancer triplet data and frontline Phase 3 plans expected to be announced ...
Transat A.T. Inc. ("Transat" or the "Company") today announced that it has mailed a letter to shareholders outlining the Board's recommendation to vote the BLUE proxy in support of Transat's eight (8) ...
Q4 2025 Earnings Call February 27, 2026 8:00 AM ESTCompany ParticipantsMichael McCarthy - Vice President of Investor ...
Morgan Stanley Direct Lending funds Fourth quarter and full year 2025 financial results were released yesterday after market close and can be accessed on the Investor Relations section of our website ...
Globant (NYSE: GLOB) today announced results for the three and twelve months ended December 31, 2025. "Twenty-three years ago, we set out to build a company that would reinvent how technology gets ...
2d
Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological ...
(Nasdaq: ADMA) ("ADMA" or the "Company"), a U.S. based, end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics, today announced its ...
Rapid developments in decarbonisation policy, feedstock availability, and refinery-scale process innovation have significantly changed the renewable diesel and biodiesel sector over the past few years ...
Delivered first clinical validation of the Recursion full stack AI Operating System in FAP, demonstrating translation from AI-driven biological insight to meaningful patient outcomes; multiple clinica ...
A new publication DOI 10.29026/oes.2026.250031, discusses an integrated metasurface-freeform system enabled multi-focal ...
Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company antici ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results